Protective effect of bifidobacteria in an experimental model ofClostridium difficileassociated colitis (original) (raw)

Protective Effects of Bifidobacterial Strains Against Toxigenic Clostridium difficile

Frontiers in Microbiology, 2018

Probiotics might offer an attractive alternative to prevent and control Clostridium difficile (C. difficile) infection (CDI). Limited information is available on the ability of commercially used bifidobacterial strains to inhibit C. difficile. This study examined the anti-clostridial effects of Bifidobacterium longum JDM301, a widely used commercial probiotic strain in China, in vitro and in vivo. In vitro evaluation revealed a significant reduction in C. difficile counts when JDM301 was co-cultured with C. difficile, which was correlated with the significant decrease in clostridial toxin titres (TcdA and TcdB). Furthermore, the cellfree culture supernatants (CFS) of JDM301 inhibited C. difficile growth and degraded TcdA and TcdB. Notably, the results showed that acid pH promoted the degradation of TcdA by CFS from JDM301. Furthermore, comparative studies among 10 B. longum strains were performed, which showed that the inhibitory effect of CFS from JDM301 was similar with the other 8 B. longum strains and higher than strain BLY1. However, when it was neutralized, the significant different was lost. When present together, it was suggested that the acid pH induced by probiotics not only played important roles in the growth inhibition against C. difficile resulting in the reduction of toxins titres, but also directly promoted the degradation of clostridial toxin. In vivo studies proved that JDM301 partially relieved damage to tissues caused by C. difficile and also decreased the number of C. difficile and toxin levels. In summary, our results demonstrated that the commercial strain, JDM301 could be considered a probiotic able to exert anti-toxin capability and most of the CFS from Bifidobacterium were able to inhibit the growth of C. difficile, depending on acid pH. These results highlighted a potential that JDM301 could be helpful in preventing CDI and that most of the bifidobacterial strains could (at least partially) exert protective effects by reducing toxin titres through growth inhibition against toxigenic C. difficile.

Safety and Protective Effect of Bifidobactérium Spp. Used as Probiotic Agent in Vivo Against Enteropathogenic Escherichia Coli

Innovative Romanian Food Biotechnology, 2015

This study showed the effect of fermented milk with Bifidobacterium bifidum on the contaminations by Escherichia coli enteropathogenic EPEC and intestinal disorders. The B. bifidum strain (Bf) was isolated on MRS medium containing 0.5g/L of cysteine hydrochloride and 2 mg/L of nalidixic acid. This strain was isolated from breast- fed infant feces. This strain is considered as a model strain, for antagonism in vivo developed in the rat (wistar). It has has been demonstrated that the administration of Bifidobacterium strain cause a significant reduction of the rate of E. coli enteropathogenic multiplication in the rats feces. Results of the macroscopic study of histological sections have confirmed the positive effect of treatment with bifidobacteria. In this study, the effect of Bifidobacterium addition in reducing the enteropathogenic bacteria effect in the digestive tract was confirmed by in vitro and in vivo conditions.

Antibacterial Effects of Compound Bifilact on E.coli and Campylobacter jejuni

Medical Laboratory Journal, 2020

Background and Objectives: Probiotics are live microorganisms that function through various mechanisms and affect the alteration of the commensal microbiota against pathogens. Nowadays, given the problems associated with antibiotics use, probiotic strains offer a novel and appropriate alternative for the treatment of diseases such as diarrhea. The aim of this study was to investigate the antibacterial synergism of Lactobacillus spp., Bifidobacterium spp. and Escherichia coli strain Nissle 1917 (ECN) on the clinical sample of diarrheagenic E.coli and Campylobacter jejuni. Methods: A paper disk-diffusion technique was used to evaluate the antibacterial activity. Sterile 6 mm paper disks were saturated with probiotic suspensions made by settling probiotic medications into distilled water. Three kinds of disk were prepared. One disk was prepared for Lactobacillus spp. and Bifidobacterium spp., another for ECN, and the third was made by combined probiotics. Clinical samples of diarrheagenic E.coli and Campylobacter jejuni were cultivated on Muller Hinton agars, and disks were placed on the inoculated Muller Hinton agars. All plates were incubated under microaerophilic and appropriate conditions. Results: The zone of inhibition (ZOI) of the bacterial growth was measured. All pathogenic microorganisms showed sensitivity to the probiotic disks. The combined disks had better effects against pathogens compared with single disks. Conclusion: A considerable synergistic effect was observed in the results of combined probiotics; therefore, combined strains can be more efficient against intestinal pathogens in comparison with single probiotics.

Treatment with Bifidobacterium longum 51A attenuates intestinal damage and inflammatory response in experimental colitis

Beneficial Microbes, 2019

This study evaluated the effects of Bifidobacterium longum 51A on the intestinal mucosa and inflammatory response in experimental colitis. Colitis was induced by administration of 3.5% dextran sodium sulphate (DSS) solution for 7 days. Two periods of administration were performed: treatment (T) group, mice received Bifidobacterium only during disease induction (7 days); total treatment (TT) group, mice received Bifidobacterium for 10 days before and during disease induction. The probiotic effects on intestinal permeability, inflammatory infiltrate, histological analysis, cytokines, chemokines and sIgA were evaluated. Bifidobacterium administration in the T group showed reduction in intestinal permeability and lower IL-1β, myeloperoxidase, and eosinophil peroxidase levels compared to those in the colitis group (P<0.05). Bifidobacterium administration in the TT group attenuated severe lesions in the colon and reduced eosinophil peroxidase level (P<0.05). B. longum 51A treatment ...

Evaluation of in vitro antagonism and protection against enteropathogenic experimental challenge of different strains of Bifidobacterium

2013

Gastrointestinal microflora highly impacts their host mainly by performing a great variety of metabolic activities, protecting the host from pathogenic colonization. Mother's milk is a prebiotic factor which stimulates bifidobacteria growth in vivo. All strains of bifidobacteria were isolated on MRS medium (in addition to 0.05% cysteine HCL and 2 mg/l of nalidixic acid) from different origins (breast-fed infant faeces and yoghurt (bifidus). The strains belong to the following species: Bifidobacterium longum, B. Breve, B. bifidum. We studied the antagonist power of Bifidobacterium against enteropathogenes (S. aureus, Escherichia coli, P. aeruginosa, Salmonella. Sp), using agar diffusion method. In vitro antagonism test showed that our strains were able to produce antagonistic substances against various pathogenic microorganisms. The activity was completely destroyed by the action of proteolytic enzymes, indicating that the biologically active portion is proteinaceous. These prope...

Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens

FEMS Microbiology Reviews, 2004

The gastrointestinal tract is a complex ecosystem that associates a resident microbiota and cells of various phenotypes lining the epithelial wall expressing complex metabolic activities. The resident microbiota in the digestive tract is a heterogeneous microbial ecosystem containing up to 1 Â 10 14 colony-forming units (CFUs) of bacteria. The intestinal microbiota plays an important role in normal gut function and maintaining host health. The host is protected from attack by potentially harmful microbial microorganisms by the physical and chemical barriers created by the gastrointestinal epithelium. The cells lining the gastrointestinal epithelium and the resident microbiota are two partners that properly and/or synergistically function to promote an efficient host system of defence. The gastrointestinal cells that make up the epithelium, provide a physical barrier that protects the host against the unwanted intrusion of microorganisms into the gastrointestinal microbiota, and against the penetration of harmful microorganisms which usurp the cellular molecules and signalling pathways of the host to become pathogenic. One of the basic physiological functions of the resident microbiota is that it functions as a microbial barrier against microbial pathogens. The mechanisms by which the species of the microbiota exert this barrier effect remain largely to be determined. There is increasing evidence that lactobacilli and bifidobacteria, which inhabit the gastrointestinal microbiota, develop antimicrobial activities that participate in the host's gastrointestinal system of defence. The objective of this review is to analyze the in vitro and in vivo experimental and clinical studies in which the antimicrobial activities of selected lactobacilli and bifidobacteria strains have been documented.

Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants

Anaerobe, 2006

The antimicrobial and anti-adhesive effects of extracellular factors from 27 strains of bifidobacteria isolated from healthy infants were tested against two reference strains of Clostridium difficile (ATCC 9689 and ATCC 43593). All bifidobacterial supernatants at pHs between 5.0 and 4.1 were able to produce strain-dependent growth inhibition of clostridia in the agar-diffusion assay. Six strains of Bifidobacterium produced during growth extracellular factors able to antagonize the adhesion of C. difficile ATCC 9689 and ATCC 43593 to cultured human enterocytes (Caco-2/TC7). Factors responsible for the anti-adhesive effect were thermolabile, active at neutral pH and unaffected by proteolytic cleavage (proteinase K and chymotrypsin). Results of the present paper show the potential of selected bifidobacteria to antagonize key mechanisms involved in the virulence of C. difficile.

Bifidobacterium longum subsp. infantis CECT7210 (B. infantis IM-1®) Displays In Vitro Activity against Some Intestinal Pathogens

Nutrients

Certain non-digestible oligosaccharides (NDO) are specifically fermented by bifidobacteria along the human gastrointestinal tract, selectively favoring their growth and the production of health-promoting metabolites. In the present study, the ability of the probiotic strain Bifidobacterium longum subsp. infantis CECT7210 (herein referred to as B. infantis IM-1®) to utilize a large range of oligosaccharides, or a mixture of oligosaccharides, was investigated. The strain was able to utilize all prebiotics screened. However, galactooligosaccharides (GOS), and GOS-containing mixtures, effectively increased its growth to a higher extent than the other prebiotics. The best synbiotic combination was used to examine the antimicrobial activity against Escherichia coli, Cronobacter sakazakii, Listeria monocytogenes and Clostridium difficile in co-culture experiments. C. difficile was inhibited by the synbiotic, but it failed to inhibit E. coli. Moreover, Cr. sakazakii growth decreased during ...

Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens

Journal of Applied Microbiology, 2006

Aim: To develop in vitro assays for comparing the antagonistic properties and anti-oxidative activity of probiotic Lactobacillus and Bifidobacterium strains against various entero-and urinary pathogens. Methods and Results: The antagonistic activity of five probiotic lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus fermentum ME-3, Lactobacillus acidophilus La5, Lactobacillus plantarum 299v and Lactobacillus paracasei 8700:2) and two bifidobacteria (Bifidobacterium lactis Bb12, Bifidobacterium longum 46) against six target pathogens was estimated using different assays (solid and liquid media, anaerobic and microaerobic cultivation) and ranked (low, intermediate and high). Bacterial fermentation products were determined by gas chromatography, and the total anti-oxidative activity of probiotics was measured using linolenic acid test. Pyelonephritic Escherichia coli was highly suppressed by GG and both bifidobacteria strains. Lactobacilli strains 8700:2, 299v and ME-3 were the most effective against Salmonella enterica ssp. enterica in microaerobic while ME-3 and both bifidobacteria expressed high activity against Shigella sonnei in anaerobic milieu. Lact. paracasei, Lact. rhamnosus and Lact. plantarum strains showed intermediate antagonistic activity against Helicobacter pylori under microaerobic conditions on solid media. The highest antioxidative activity was characteristic for Lact. fermentum ME-3 (P < 0AE05). No efficient antagonist against Clostridium difficile was found. The positive correlations between the pH, lactic acid production and anti-microbial activity for all tested probiotics were assessed. Conclusions: Developed experimental assays enable to compare the anti-microbial and-oxidative activity of Lactobacillus and/or Bifidobacterium probiotics, which have been claimed to possess the ability of suppressing the growth of various enteric and urinary pathogens. Significance and Impact of the Study: Screening Lactobacillus and Bifidobacterium sp. strains according to their activity in various environmental conditions could precede the clinical efficacy studies for adjunct treatment with probiotics in cure of different gastrointestinal and urinary tract infections.